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M
arkers of fatty liver such as ␥-glutamyltransferase (GGT) are independently associated with an increased risk of type 2 diabetes (1). Some recent studies have shown that hyperferritinemia may also predict new-onset type 2 diabetes (2) .
We assessed the cross-sectional relationships between ferritin, GGT, and glucose intolerance status in a large cohort of adults. We performed a retrospective analysis on the database of our clinical chemistry laboratory to retrieve results of serum ferritin, GGT, lipids, glucose (fasting plasma glucose [FPG] ), and C-reactive protein (high-sensitivity C-reactive protein [hs-CRP]) tests, which were performed on the whole cohort of outpatient adults (aged Ն35 years) consecutively referred by general practitioners for routine blood testing over the past 2 years. Fasting GGT, FPG, and lipids were measured by standard enzymatic procedures (Roche Diagnostics), ferritin by a chemiluminescence assay (DiaSorin-Liaison), and hs-CRP by a nephelometric assay (Dade-Behring).
We used separate multivariable logistic regression analyses to examine the interaction relationships with impaired fasting glycemia (impaired fasting glucose
[IFG] as defined by an FPG value Ն5.6 mmol/l) or diabetes (FPG value Ն7.1 mmol/l) as the dependent variables predicted from ferritin quartiles (Ͻ42, 42-80, 80 -156, and Ն156 g/l) within the quartiles of GGT (Ͻ16, 16 -25, 26 -35, and Ն36 units/l). Adjusting variables were sex, age, lipids, and hs-CRP.
Cumulative results of FPG and ferritin were retrieved for 2,637 individuals. After excluding subjects with C-reactive protein Ͼ10 mg/l (because inflammation may increase ferritin) and those with very low ferritin, which might be due to anemia (Ͻ15 g/l), and very high ferritin, which might be due to hemochromatosis (Ͼ400 g/l in men and Ͼ300 g/l in women), the final study population consisted of 2,449 subjects (63% female) with a mean Ϯ SD (range) age of 61.8 Ϯ 15 years (35-107). Overall, 161 (6.6%) subjects had a FPG value Ն7.1 mmol/l, and 559 (22.8%) subjects had IFG. Mean GGT and ferritin concentrations were 33 Ϯ 46 units/l and 108 Ϯ 84 g/l, respectively.
Although the prevalence rates of ferritin quartiles increased steadily across IFG/diabetes categories (ranging from 17 to 27% for IFG and from 4 to 8% for diabetes; P Ͻ 0.0001), these prevalences remarkably varied by GGT quartiles. As GGT increased, the prevalence rates of ferritin quartiles across IFG/diabetes categories strengthened (P Ͻ 0.001 for interaction). For example, within the lowest GGT quartile, ferritin quartiles were not associated with IFG (ranging from 12.7 to 14.5%) or diabetes (from 1.2 to 1.5%), in contrast to the highest GGT quartile, wherein the prevalence rates ranged from 19.2 to 28.3% for IFG and from 9.4 to 13.5% for diabetes (P Ͻ 0.01). These results remained significant even after adjustment for sex, age, lipids, and hs-CRP.
Our findings, although only correlative in nature, indicate that ferritin is associated with a greater frequency of IFG or diabetes only among those with highnormal GGT (Ն36 units/l), not in those with low-normal GGT, and suggest that ferritin itself might not be a sufficient risk factor for developing IFG/diabetes. The association between increased GGT and glucose intolerance might be explained by some underlying, biological, mechanisms such as enhanced oxidative stress, insulin resistance, and fatty liver (3). 
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